Positive JAK2, CALR or MPL Post-Transplant: What Now?

A positive or rising test for your original myelofibrosis driver mutation (JAK2, CALR, or MPL) after a stem cell transplant is an important warning signal, but it does not automatically mean your transplant has failed. It indicates that mutant DNA from the original disease is still present or returning ^[1][2]. Modern molecular tests are very sensitive, meaning they can detect the molecular signs of the disease before changes in your standard blood counts occur ^[3][4]. Doctors use these early warnings to investigate further and, if necessary, take action before a clinical relapse (a return of abnormal blood counts, symptoms, and bone marrow scarring) happens ^[5].

Understanding the Test: Minimal Residual Disease (MRD)

To monitor your recovery, doctors look for minimal residual disease (MRD)—the presence of mutant DNA that might remain after treatment ^[4]. The lab report will often provide a number called the variant allele fraction (VAF) or allele burden, which represents the proportion of mutant DNA detected.

Specialized laboratory techniques, such as digital PCR or quantitative PCR, are used for this post-transplant testing ^[6]. These tests are highly sensitive, but they have a limit of detection (the smallest amount of mutant DNA the test can spot) and a limit of quantitation (the smallest amount it can measure accurately).

Because different mutations clear at different rates, some patients may still have detectable mutant DNA in the early months (like day 30 or day 100) after transplant ^[7]. To understand what your current number means, doctors compare it to your baseline—the amount of mutant DNA you had before the transplant, measured using the exact same test and sample type (blood versus bone marrow) ^[7][4].

Why Trends Matter More Than a Single Result

A single low-level positive result can be frightening, but it does not automatically equal a full molecular relapse (a confirmed, reproducible return or rise of the mutation). Molecular tests can fluctuate, and a result right at the edge of the test’s detection limit might reflect normal assay variability rather than a true return of disease.

Doctors look for a trend across multiple tests ^[1]:

• Declining levels: This is a reassuring sign that the disease is continuing to clear.
• Stable low levels: This may represent a persistent small group of mutated cells without an active clinical relapse, or it may simply be assay variation.
• Steadily rising levels: A confirmed rise across multiple tests, or a mutation that returns after previously being undetectable, is a stronger sign that the myelofibrosis may be returning ^[1][3].

Getting the Full Picture

Your care team will not make major treatment decisions based solely on one molecular test. They will combine the mutation test results with other tests ^[2]:

• Donor Chimerism: This measures the percentage of blood and marrow cells that come from your donor. While 100% donor chimerism is a reassuring sign of engraftment, it does not completely rule out residual disease, especially if the malignant cells are confined to the marrow or fall below the chimerism test’s sensitivity ^[2][8].
• Complete Blood Count (CBC): Routine checks of your red blood cells, white blood cells, and platelets help determine if your bone marrow is functioning normally ^[9].
• Bone Marrow Biopsy: If your mutation levels are clearly rising, a biopsy allows the doctor to physically assess the marrow for abnormal cell growth, blasts, and returning fibrosis (scar tissue) ^[2][10].
• Spleen Size and Symptoms: Your doctor will check if your spleen is enlarging or if you have symptoms like fatigue, early fullness, or night sweats ^[11]. (Note: These symptoms are nonspecific and have many causes other than relapse; always report them to your team rather than interpreting them on your own).

What Usually Happens Next

If you receive an unexpected positive result, do not panic and do not make any medication changes on your own. The typical next steps are:

1. Confirm the result: Your doctor will likely repeat the test promptly using the same assay and specimen type to confirm a true rise ^[5].
2. Review the full clinical picture: They will look at your blood counts, donor chimerism, and overall symptoms.
3. Decide on action: Together, you will decide if closer monitoring, a bone marrow biopsy, or a change in treatment is appropriate.

Important Safety Warning

Never reduce or stop your immunosuppression medications (like tacrolimus, cyclosporine, or steroids) on your own. Tapering these drugs requires strict medical supervision. Changing your dose can trigger severe, life-threatening graft-versus-host disease (GVHD), where the donor cells attack your healthy organs. Promptly report any new rash, severe diarrhea, jaundice, fever, or bleeding to your transplant team.

Taking Action: Options if the Mutation is Rising

If repeat testing confirms a molecular relapse, your transplant team will create an individualized plan. While there is no single universally accepted treatment, options may be considered based on your specific situation ^[5]:

• Immunosuppression Taper: Under close supervision, doctors may slowly lower your immunosuppression medications ^[12][13]. This can sometimes allow the donor immune cells to recognize and attack the remaining myelofibrosis cells (the graft-versus-tumor effect), but this must be carefully balanced against the risk of triggering GVHD.
• Donor Lymphocyte Infusion (DLI): In selected patients, doctors might provide an infusion of extra white blood cells from your original donor. While DLI can help clear molecular relapses in some cases, responses vary and it carries significant risks, including severe GVHD, low blood counts, and infection ^[14][15].
• Targeted Medications: Your doctor might consider specialist-selected options like a JAK inhibitor (such as ruxolitinib) or a hypomethylating agent (a drug that alters how DNA is read). These are not guaranteed to eradicate the disease and may cause side effects, but they can help control it ^[16][17].
• Clinical Trials: Many centers test investigational approaches for managing molecular relapse.